Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $40.8 million versus the consensus estimate of $38.44 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Halozyme prices $1.3B convertible notes offering due 2033
• RBC bullish on Kraft Heinz, sees return to growth in 2027